Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of the
combination of selective internal radiation (SIR)-Spheres with yttrium-90 attached and
cetuximab. Some participants will also take erlotinib with this combination.
Yttrium-90 microspheres are designed to treat cancer that has spread to the liver.
SIR-Spheres are designed to deliver the radiation directly to the liver. This radiation may
cause the tumor cells to die.
Cetuximab and erlotinib are drugs that are designed to block the epidermal growth factor
receptor (EGFR). EGFR is a protein that helps cancer cells grow. Blocking the EGFR may stop
tumors from growing.